Collegium Pharmaceutical, Inc. is a pharmaceutical company based in the United States of America. They focus on developing and commercializing abuse-deterrent products utilized for chronic pain treatment. Their patented DETERx platform technology ensures the extended-release and safety of drugs, even against abuse methods like chewing and crushing. With a Risk Rating Score of 29.6, Collegium Pharmaceutical is considered a medium-risk company. Their product lineup includes Xtampza ER, Nucynta Products, Belbuca, and Symproic. Prioritizing environment, sustainability, and governance, these products are designed to meet ESG standards.